Table 1.
Summary of clinical characteristics and treatment outcomes of patients presented in cases 1–5.
| Case No. | Gender | Age | Smoking History | Histopathologic Diagnosis | Stage at Diagnosis | Genetic Alterations | Treatment before LEN+PEM | LEN + PEM Outcome | ||
|---|---|---|---|---|---|---|---|---|---|---|
| chemotherapy | immunotherapy | VEGF-A | ||||||||
| 1 | M | 68 | 30 PY | adenocarcinoma of lung | 4-C | MDM2, KRAS amplification, RB1 amplification, STK11 | 13 mo. | 12 mo. (combined with chemo | CR after 2 mo + | |
| 2 | M | 68 | 60 PY | adenocarcinoma of lung | 1-B | 4 mo. | 4 mo. (combined with chemo) | Significant response after 2 mo + | ||
| 3 | F | 64 | 40 PY | adenocarcinoma of lung | 4-B | 4 mo. | 4 mo (combined with chemo) | CR after 3 mo + | ||
| 4 | F | 50 | 10 PY | malignant pleural mesothelioma | 3-B | 6 mo. | 9 mo | 4 mo. (combined with chemo) | Significant response after 2 mo. + | |
| 5 | M | 61 | 35 PY | adenocarcinoma of lung | 4-C | KRAS, STK11, PDL1 < 24% | 19 mo. | 14 mo. (combined with chemo) + 11 mo. (without chemo) | 5 mo. (combined with chemo) | Stabilized disease with no adverse events for 10 mo., until patient’s sudden death. |